6CBQ

Crystal structure of QscR bound to agonist S3

  • Classification: transcription/agonist
  • Organism(s): Pseudomonas aeruginosa
  • Expression System: Escherichia coli
  • Mutation(s): No 

  • Deposited: 2018-02-05 Released: 2018-02-28 
  • Deposition Author(s): Churchill, M.E.A., Wysoczynski-Horita, C.L.
  • Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), National Institutes of Health/National Cancer Institute (NIH/NCI), National Institutes of Health/Office of the Director, National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS), National Science Foundation (NSF, United States)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.212 
  • R-Value Observed: 0.215 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Mechanism of agonism and antagonism of the Pseudomonas aeruginosa quorum sensing regulator QscR with non-native ligands.

Wysoczynski-Horita, C.L.Boursier, M.E.Hill, R.Hansen, K.Blackwell, H.E.Churchill, M.E.A.

(2018) Mol Microbiol 108: 240-257

  • DOI: 10.1111/mmi.13930
  • Primary Citation of Related Structures:  
    6CC0, 6CBQ

  • PubMed Abstract: 
  • Pseudomonas aeruginosa is an opportunistic pathogen that uses the process of quorum sensing (QS) to coordinate the expression of many virulence genes. During quorum sensing, N-acyl-homoserine lactone (AHL) signaling molecules regulate the activity of ...

    Pseudomonas aeruginosa is an opportunistic pathogen that uses the process of quorum sensing (QS) to coordinate the expression of many virulence genes. During quorum sensing, N-acyl-homoserine lactone (AHL) signaling molecules regulate the activity of three LuxR-type transcription factors, LasR, RhlR and QscR. To better understand P. aeruginosa QS signal reception, we examined the mechanism underlying the response of QscR to synthetic agonists and antagonists using biophysical and structural approaches. The structure of QscR bound to a synthetic agonist reveals a novel mode of ligand binding supporting a general mechanism for agonist activity. In turn, antagonists of QscR with partial agonist activity were found to destabilize and greatly impair QscR dimerization and DNA binding. These results highlight the diversity of LuxR-type receptor responses to small molecule agonists and antagonists and demonstrate the potential for chemical strategies for the selective targeting of individual QS systems.


    Related Citations: 
    • Potent and selective synthetic modulators of a quorum sensing repressor in Pseudomonas aeruginosa identified from second-generation libraries of N-acylated L-homoserine lactones.
      Mattmann, M.E., Shipway, P.M., Heth, N.J., Blackwell, H.E.
      (2011) Chembiochem 12: 942

    Organizational Affiliation

    Department of Pharmacology and Program in Structural Biology and Biochemistry, University of Colorado School of Medicine, Aurora, CO 80045, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
LuxR family transcriptional regulatorAB237Pseudomonas aeruginosaMutation(s): 0 
Gene Names: 
Find proteins for Q9RMS5 (Pseudomonas aeruginosa)
Explore Q9RMS5 
Go to UniProtKB:  Q9RMS5
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EVY
Query on EVY

Download CCD File 
A, B
(2S)-2-hexyl-N-[(3S)-2-oxooxolan-3-yl]decanamide
C20 H37 N O3
XGYNUFAUHRHVSH-ROUUACIJSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.212 
  • R-Value Observed: 0.215 
  • Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 94.12α = 90
b = 94.12β = 90
c = 105.68γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
d*TREKdata reduction
d*TREKdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesGM109403
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesP30CA046934
National Institutes of Health/Office of the DirectorUnited StatesS10OD012033
National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS)United StatesUL1TR001082
National Institutes of Health/Office of the DirectorUnited StatesS10OD12073
National Science Foundation (NSF, United States)United StatesDMR-1121288

Revision History 

  • Version 1.0: 2018-02-28
    Type: Initial release
  • Version 1.1: 2018-05-09
    Changes: Data collection, Database references
  • Version 1.2: 2019-11-27
    Changes: Author supporting evidence